Orgenesis Inc stock (US68621F1021): delisting to OTC puts spotlight on business model and risks

Orgenesis Inc has been delisted from Nasdaq and moved to OTC trading, while the share price recently showed extreme volatility. What stands behind the cell and gene therapy specialist’s stock story, and what should US retail investors know about its business drivers?

Orgenesis Inc, a cell and gene therapy-focused biotech company, has drawn renewed attention from speculative investors after its stock was delisted from Nasdaq and moved to over-the-counter (OTC) trading, according to a corporate actions overview by Robinhood published in 2026 that notes the transition of Orgenesis Inc. (ticker ORGS) to the OTC market. At the same time, separate market data portals recently reported unusually large percentage moves in the thinly traded shares, underscoring the high volatility and liquidity risk often associated with micro-cap biotech names.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Orgenesis Inc
• Sector/industry: Biotechnology, cell and gene therapy
• Headquarters/country: Germantown, Maryland, United States
• Core markets: Advanced therapy development and manufacturing, primarily United States and Europe
• Key revenue drivers: Development and services related to cell and gene therapies and collaboration agreements
• Home exchange/listing venue: OTC market in the United States (previously Nasdaq under ticker ORGS)
• Trading currency: US dollar (USD)

Orgenesis Inc: core business model

Orgenesis Inc positions itself as a technology and services company in the cell and gene therapy field, focusing on enabling decentralized and point-of-care manufacturing of advanced therapies. The company describes a platform that aims to bring complex treatments closer to patients and healthcare providers by using modular production units and standardized processes, according to the company’s own information on its website as of 2026. This approach is designed to reduce costs and logistical hurdles that often hamper the roll-out of personalized treatments.

The business model combines proprietary technologies with a network of partnerships involving hospitals, research centers and industry groups. Orgenesis Inc emphasizes that it works to integrate process development, regulatory support and manufacturing know-how, rather than focusing solely on a single lead drug candidate, according to its corporate presentation materials referenced on the investor relations pages as of 2025. This service-oriented strategy differs from many traditional biotech peers, which often rely on a small number of high-risk clinical assets.

In addition to its technology platforms, Orgenesis Inc has historically pursued collaborations where it provides development and manufacturing capabilities in exchange for fees, milestones or revenue-sharing arrangements. The company’s materials indicate that revenue is generated both from platform-related services and, in some cases, licensing of intellectual property associated with cell therapies, according to filings and corporate documents made available on the investor relations site as of 2024. Such a mix of service income and potential longer-term upside from partnered programs can make the revenue profile more diversified but also dependent on partners’ progress and funding.

Main revenue and product drivers for Orgenesis Inc

For Orgenesis Inc, key revenue drivers have included development services and technology access provided to healthcare partners that are exploring cell and gene therapies. Company communications in recent years have highlighted projects in areas such as immunotherapies and regenerative medicine, where Orgenesis Inc contributes manufacturing process expertise and platform technologies, according to investor materials published on the company’s website as of 2023 and 2024. These arrangements typically involve multi-year collaboration frameworks.

The company has also pointed to a pipeline of proprietary or co-developed programs that could, if successfully advanced through clinical development and regulatory review, provide additional revenue in the form of royalties or profit-sharing. However, like many biotech players, Orgenesis Inc remains exposed to the scientific and regulatory uncertainties inherent in cell and gene therapy development, and past communications have noted that timelines and outcomes can be difficult to predict, according to risk factor discussions in earlier SEC filings available via the investor relations portal as of 2023. As a result, the financial profile may fluctuate from year to year.

Beyond direct program-related income, Orgenesis Inc has invested in its so-called point-of-care or decentralized manufacturing infrastructure, which it has presented as a longer-term strategic asset. The company has described a network of facilities and modular units intended to serve hospital partners by enabling on-site production of certain cell therapies, subject to regulatory approvals and quality standards, according to company descriptions as of 2024. In theory, broader adoption of this model could increase recurring revenue from service contracts and technology fees, although the speed of uptake depends on health system investment decisions and clinical validation.

Why Orgenesis Inc matters for US investors

From a US investor perspective, Orgenesis Inc is part of the broader ecosystem of companies working on cell and gene therapies, an area that has attracted substantial interest due to its potential to transform treatment paradigms in oncology and rare diseases. The company’s operations are rooted in the United States, and it has sought to collaborate with domestic hospitals and research institutions, which ties its prospects to the pace of innovation and reimbursement decisions in the US healthcare system, according to overviews on the company’s website and investor materials as of 2024.

However, the delisting from Nasdaq and move to OTC trading, as noted in the Robinhood corporate actions tracker in 2026, significantly changes the risk profile for many retail investors. Trading on the OTC market generally involves lower liquidity, wider bid-ask spreads and, in some cases, reduced analyst coverage compared with major exchanges, according to educational notes on market structure published by US brokerage and exchange operators as of 2025. For Orgenesis Inc, this means that even relatively small order flows can lead to large price swings, amplifying volatility in both directions.

US investors evaluating the stock also need to consider the typical funding cycle of development-stage biotech companies. Orgenesis Inc has historically depended on external capital and partnership funding to support its activities, and like many peers, it has discussed the possibility of raising additional funds in previous filings, according to risk disclosures in SEC documents available via the investor relations site as of 2023. Such financing, when executed, can result in share dilution. In the OTC environment, access to capital markets can sometimes become more constrained, which may influence strategic decisions.

Industry trends and competitive position

The broader cell and gene therapy industry is characterized by rapid scientific advances, high development costs and stringent regulatory oversight. Research groups and consultancies tracking the sector have highlighted a growing number of approved therapies and late-stage programs in indications such as certain blood cancers and genetic disorders, with the US Food and Drug Administration taking an increasingly active role in shaping guidance around manufacturing standards, according to sector reports published by recognized industry analysts in 2023 and 2024. This environment creates both opportunities and compliance challenges for companies like Orgenesis Inc.

Orgenesis Inc seeks to differentiate itself by focusing on process innovation and decentralized manufacturing solutions rather than relying solely on a single flagship therapy. The company’s materials describe a vision in which hospitals and clinics can produce certain personalized therapies on site using standardized technology platforms, potentially shortening supply chains and reducing costs, according to corporate descriptions on its website as of 2024. This model positions Orgenesis Inc more as an enabler or infrastructure provider within the ecosystem, which could make it complementary to traditional biotech firms that prioritize clinical assets.

Competition, however, remains intense. Established contract development and manufacturing organizations, as well as specialized cell therapy production companies, are investing heavily in their own platforms and capacity. Large pharmaceutical and biotech companies are also building internal capabilities and forming strategic partnerships to secure manufacturing expertise, according to deal summaries and sector news from major financial media as of 2024. For Orgenesis Inc, maintaining a competitive edge may require continued investment in technology, regulatory compliance and partnership-building, all of which depend on sufficient financial resources and operational execution.

Risks and open questions

For Orgenesis Inc, the shift from a major exchange to the OTC market underscores several risks that investors commonly monitor. First, the stock’s liquidity is likely to be lower than during its Nasdaq listing period, which can increase transaction costs and make it harder for larger investors to build or unwind positions without moving the market. OTC-listed micro-cap biotech stocks are also more vulnerable to sharp price spikes or drops driven by limited news flow and speculative trading, as highlighted by the outsized percentage moves recently observed on some market data platforms reporting on ORGS.

Second, the company’s long-term financial sustainability remains an open question typical for development-focused biotechs. Orgenesis Inc’s previous filings have referenced recurring operating losses and the need for continued funding to support research, development and commercialization efforts, according to risk factor discussions in SEC documents as of 2023. If access to capital becomes more difficult or expensive, management could be forced to prioritize certain projects over others, potentially affecting growth prospects and timelines for its decentralized manufacturing initiatives.

Third, regulatory and technical risks are inherent in cell and gene therapy manufacturing. Achieving consistent quality at scale, meeting evolving FDA and international standards, and managing complex supply chains pose significant challenges for all players in the field. Orgenesis Inc’s strategy of enabling point-of-care manufacturing requires close coordination with hospital partners and regulators to ensure that on-site production meets Good Manufacturing Practice requirements, as discussed in the company’s own descriptions of its operating model as of 2024. Any setbacks in this area could slow adoption and affect revenue.

Conclusion

Orgenesis Inc occupies a niche within the cell and gene therapy landscape by focusing on decentralized manufacturing and service-based collaborations, rather than relying solely on a single breakthrough drug candidate. The company’s vision of enabling point-of-care production aligns with broader industry efforts to make advanced therapies more accessible, but execution depends on regulatory approvals, partner engagement and sustained funding. For US investors, the stock’s transition from Nasdaq to OTC trading, combined with its micro-cap status and development-stage profile, highlights elevated volatility and liquidity risk alongside the potential upside associated with emerging biotech technologies. A balanced assessment therefore requires careful attention to the company’s financial disclosures, partnership progress and any future updates from management on strategic priorities.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.